MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
With the MEI Board aligned around our strategy, we have a productive framework to advance both clinical programs in a manner intended to address significant medical needs while prioritizing a measured and objective-based allocation of our resources,” said David Urso, president and chief executive officer of MEI Pharma.
- With the MEI Board aligned around our strategy, we have a productive framework to advance both clinical programs in a manner intended to address significant medical needs while prioritizing a measured and objective-based allocation of our resources,” said David Urso, president and chief executive officer of MEI Pharma.
- The plan builds on encouraging recently reported voruciclib clinical data and ME-344 data separately reported today.
- Under the plan, the ongoing voruciclib development strategy will be guided by future clinical trial results and applicable regulatory authority advice.
- The goal of the formulation effort is to increase biological activity, improve patient convenience of administration and increase commercial opportunity.